ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims
An FDA warning that promotional materials pushed unsupported cure‑all claims for Anktiva set off the investor actions.
Overview
- Plaintiff firms say investors who bought ImmunityBio shares between Jan. 19 and Mar. 24, 2026 have until May 26, 2026 to seek lead‑plaintiff status.
- The lawsuits follow an FDA warning letter dated March 13, 2026 that called a TV ad and a January podcast about Anktiva false or misleading.
- Regulators said the messages implied Anktiva could cure or prevent all cancers and promised long‑term cancer‑free results for all bladder cancer patients without supporting data, even though Anktiva is only approved for a form of non‑muscle invasive bladder cancer.
- After the letter became public on March 24, 2026, ImmunityBio’s shares fell more than 21%, cutting roughly $2 billion from the company’s market value.
- Complaints invoke Exchange Act Sections 10(b) and 20(a) and SEC Rule 10b‑5, define a Jan. 19–Mar. 24 class period, and remain at an early stage with no class certified.